Arthritis news and arthritis widget

Biotechnology company Arana Therapeutics Limited (ASX: AAH) announced that lead anti-inflammatory compound, ART621 has successfully passed review of its rheumatoid arthritis Investigational New Drug (IND) application by the US Food and Drug Administration (FDA). IND status indicates regulatory approval to conduct clinical trials in humans in the United States and represents the first review of ART621 data by a major Regulatory Authority.

Significant increases in surgical capacity or diverting patients to other jurisdictions are the best ways to deal with excessive wait times for hip and knee replacement surgery - a leading symbol of underfunding in Canada's healthcare system. Politically popular strategies, such as wait time guarantees, are not likely to have much impact, according to a new study.

Only six months after undergoing a unique and innovative surgery at Michigan State University, Jake - part dog and now part machine - spends his time working out on an underwater treadmill, traversing obstacle courses and prancing around pain free. Jake, an 11-year-old yellow Labrador retriever, was the first dog in the Midwest and only the 11th in the world to undergo surgery for a new, cementless elbow prosthesis last April.

African Americans are more wary of the risks of rheumatoid arthritis (RA) treatment and whites are optimistic about their benefits, according to research funded in part by the Arthritis Foundation and presented this week at the American College of Rheumatology Annual Scientific Meeting in San Francisco. Research shows that African Americans and white Americans differ in their healthcare utilization. However, the reasons behind this difference are not apparent.

Disability and a recent diagnosis of rheumatoid arthritis (RA) are associated with a greater risk for depression according to research funded by the Arthritis Foundation and presented this week at the American College of Rheumatology Annual Scientific Meeting in San Francisco. Studies show that people with RA who are depressed have worse outcomes - including death - as compared to people with RA who are not depressed.

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the publication of preclinical results for 2ME2 (Panzem or 2-methoxyestradiol) in rheumatoid arthritis (RA). The results of the study, conducted by EntreMed collaborator, Dr. Ernest Brahn, Professor of medicine, Rheumatology Program Director, David Geffen School of medicine at UCLA, were published in the November 2008 issue of the Journal of Rheumatology (Brahn E, Banquerigo ML, Lee JK, Park EJ, Fogler WE, and Plum SM. read more